Samsung Biologics Co Ltd Capital Reinvestment Ratio
Samsung Biologics Co Ltd capital reinvestment ratio. Samsung Biologics Co Ltd (207940) has a Capital Reinvestment Ratio of 0.16x as of June 2026, meaning it reinvests 0% of its operating cash flow (₩624.80 Billion) in capital expenditures (₩99.08 Billion). Check Samsung Biologics Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Samsung Biologics Co Ltd (2017–2025)
Capital reinvestment ratio of Samsung Biologics Co Ltd from 2017 to 2025. This chart tracks Samsung Biologics Co Ltd's Capital Reinvestment Ratio across 8 annual periods. Also explore 207940 net assets growth trend to track the company's year-over-year net asset growth rate.
Samsung Biologics Co Ltd Capital Reinvestment Ratio by Year (2017–2025)
Samsung Biologics Co Ltd capital reinvestment ratio by year from 2017 to 2025. For the full cash flow conversion analysis, see Samsung Biologics Co Ltd (207940) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | ₩2.25 Trillion | ₩1.48 Trillion | ▼ -21.0% |
| 2024 | 0.83x | ₩1.66 Trillion | ₩1.38 Trillion | ▲ +25.2% |
| 2023 | 0.66x | ₩1.67 Trillion | ₩1.11 Trillion | ▼ -33.9% |
| 2022 | 1.00x | ₩953.05 Billion | ₩956.84 Billion | ▲ +12.3% |
| 2021 | 0.89x | ₩454.60 Billion | ₩406.25 Billion | ▲ +29.3% |
| 2020 | 0.69x | ₩202.09 Billion | ₩139.66 Billion | ▼ -96.4% |
| 2019 | 18.99x | ₩10.15 Billion | ₩192.84 Billion | ▲ +475.8% |
| 2017 | 3.30x | ₩149.82 Billion | ₩494.12 Billion | — |